Literature DB >> 29196147

Mast Cells as Drivers of Disease and Therapeutic Targets.

Frank Siebenhaar1, Frank A Redegeld2, Stephan C Bischoff3, Bernhard F Gibbs4, Marcus Maurer5.   

Abstract

Mast cells (MCs) contribute to the pathogenesis of a multitude of diseases that include MC-driven disorders such as urticaria, type I allergies, and mastocytosis as well as autoimmune and other inflammatory disorders and malignant tumors. Here, we review and discuss the results of studies that identified and characterized how MCs contribute to disease and, importantly, what strategies may be used to target MCs and MC effects therapeutically. Specifically, we discuss the most common approaches for investigating the role and relevance of MCs in various diseases. We also review current therapeutic approaches aimed at modulating MC numbers, inhibiting MCs and/or preventing MC activation, modulating MC signal transduction and protection from the effects of MC mediators.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29196147     DOI: 10.1016/j.it.2017.10.005

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  39 in total

Review 1.  Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?

Authors:  Theoharis C Theoharides; Irene Tsilioni; Huali Ren
Journal:  Expert Rev Clin Immunol       Date:  2019-04-22       Impact factor: 4.473

2.  Substance P and IL-33 administered together stimulate a marked secretion of IL-1β from human mast cells, inhibited by methoxyluteolin.

Authors:  Alexandra Taracanova; Irene Tsilioni; Pio Conti; Errol R Norwitz; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-19       Impact factor: 11.205

3.  Fluvastatin enhances IL-33-mediated mast cell IL-6 and TNF production.

Authors:  Marcela T Taruselli; Elizabeth Motunrayo Kolawole; Amina Abdul Qayum; Tamara T Haque; Heather L Caslin; Daniel Abebayehu; Sydney A Kee; Jordan M Dailey; Kaitlyn G Jackson; Jason R Burchett; Andrew J Spence; Neha Pondicherry; Brian O Barnstein; Gregorio Gomez; David B Straus; John J Ryan
Journal:  Cell Immunol       Date:  2021-11-24       Impact factor: 4.868

Review 4.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

5.  In vivo non-invasive staining-free visualization of dermal mast cells in healthy, allergy and mastocytosis humans using two-photon fluorescence lifetime imaging.

Authors:  Marius Kröger; Jörg Scheffel; Viktor V Nikolaev; Evgeny A Shirshin; Frank Siebenhaar; Johannes Schleusener; Jürgen Lademann; Marcus Maurer; Maxim E Darvin
Journal:  Sci Rep       Date:  2020-09-10       Impact factor: 4.379

6.  Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRI-mediated signaling.

Authors:  Jelle Folkerts; Frank Redegeld; Gert Folkerts; Bart Blokhuis; Mariska P M van den Berg; Marjolein J W de Bruijn; Wilfred F J van IJcken; Tobias Junt; See-Ying Tam; Stephen J Galli; Rudi W Hendriks; Ralph Stadhouders; Marcus Maurer
Journal:  Allergy       Date:  2020-04-24       Impact factor: 13.146

7.  Inflammation and tumor progression: signaling pathways and targeted intervention.

Authors:  Huakan Zhao; Lei Wu; Guifang Yan; Yu Chen; Mingyue Zhou; Yongzhong Wu; Yongsheng Li
Journal:  Signal Transduct Target Ther       Date:  2021-07-12

Review 8.  The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis.

Authors:  Lai-San Wong; Yu-Ta Yen; Chih-Hung Lee
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

Review 9.  The Interplay between the Immune and the Endocannabinoid Systems in Cancer.

Authors:  Mariantonia Braile; Simone Marcella; Gianni Marone; Maria Rosaria Galdiero; Gilda Varricchi; Stefania Loffredo
Journal:  Cells       Date:  2021-05-21       Impact factor: 6.600

10.  IgE-Induced Mast Cell Activation Is Suppressed by Dihydromyricetin through the Inhibition of NF-κB Signaling Pathway.

Authors:  Tsong-Min Chang; Tzu-Chih Hsiao; Ting-Ya Yang; Huey-Chun Huang
Journal:  Molecules       Date:  2021-06-25       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.